<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04370301</url>
  </required_header>
  <id_info>
    <org_study_id>RG1006957</org_study_id>
    <secondary_id>NCI-2020-02422</secondary_id>
    <secondary_id>10441</secondary_id>
    <secondary_id>P30CA015704</secondary_id>
    <nct_id>NCT04370301</nct_id>
  </id_info>
  <brief_title>Reduced Intensity Haploidentical Transplantation for the Treatment of Primary or Secondary Myelofibrosis</brief_title>
  <official_title>Pilot Study of JAK Inhibitor Therapy Followed by Reduced Intensity Haploidentical Transplantation for Patients With Myelofibrosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fred Hutchinson Cancer Research Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Fred Hutchinson Cancer Research Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase II trial studies the outcomes of using a JAK inhibitor prior to reduced intensity&#xD;
      haploidentical (Haplo) transplantation for the treatment of primary or secondary&#xD;
      myelofibrosis (MF). Haplo transplant has been shown to be safe and effective in patients with&#xD;
      leukemia and lymphoma who don't have an available sibling donor. The primary risk of using&#xD;
      Haplo HCT in patients with MF is graft failure as the graft failure rate has been&#xD;
      historically higher with Haplo HCT than with other donor sources and higher with MF patients&#xD;
      due to bone marrow fibrosis than in patients with other hematologic malignancies. JAK&#xD;
      inhibitors when used in patients with MF may decrease the size of the spleen and decrease&#xD;
      inflammation in the bone marrow. Therefore using a JAK inhibitor prior to Haplo transplant&#xD;
      has the potential to decrease graft failure in patients with MF. Haplo transplants for&#xD;
      patients with MF have been done successfully at multiple institutions in patients not on a&#xD;
      study and are currently being covered by Medicare.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OUTLINE:&#xD;
&#xD;
      JAK INHIBITOR THERAPY: Patients receive a JAK inhibitor at least 8 weeks prior to the start&#xD;
      of hematopoietic cell transplantation (HCT) conditioning through day -4 before&#xD;
      transplantation.&#xD;
&#xD;
      CONDITIONING: Patients receive melphalan intravenously (IV) over 1 hour on day -5,&#xD;
      fludarabine IV over 30-60 minutes on days -5 to -2, and undergo total-body irradiation (TBI)&#xD;
      on day -1.&#xD;
&#xD;
      TRANSPLANT: Patients receive peripheral blood stem cell infusion on day 0.&#xD;
&#xD;
      GVHD PROPHYLAXIS: Patients then receive cyclophosphamide IV over 3 hours on days 3-4,&#xD;
      tacrolimus IV beginning day 5 then orally (PO) for 6 months, mycophenolate mofetil PO twice&#xD;
      daily (BID) or three times daily (TID) beginning day 5 for 6 weeks, and granulocyte&#xD;
      colony-stimulating factor (G-CSF) subcutaneously (SC) beginning day 7 until neutrophil&#xD;
      recovery is &gt; 1,500/mm^3.&#xD;
&#xD;
      After completion of study treatment, patients are followed up between day 80-100, at 1 year,&#xD;
      and then up to 5 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 9, 2021</start_date>
  <completion_date type="Anticipated">August 31, 2028</completion_date>
  <primary_completion_date type="Anticipated">August 31, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Probability of primary and secondary graft failure</measure>
    <time_frame>Up to 3 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of severe (grade 3 or 4) cytokine release syndrome</measure>
    <time_frame>Up to 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Non-relapse mortality (NRM)</measure>
    <time_frame>Day 100</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>NRM</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence and severity of acute and chronic graft versus host disease (GVHD)</measure>
    <time_frame>Up to 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of relapse</measure>
    <time_frame>At 1 year</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Primary Myelofibrosis</condition>
  <condition>Secondary Myelofibrosis</condition>
  <arm_group>
    <arm_group_label>Treatment (JAK inhibitor, conditioning, GVHD prophylaxis)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>JAK INHIBITOR THERAPY: Patients receive a JAK inhibitor at least 8 weeks prior to the start of HCT conditioning through day -4 before transplantation.&#xD;
CONDITIONING: Patients receive melphalan IV over 1 hour on day -5, fludarabine IV over 30-60 minutes on days -5 to -2, and undergo TBI on day -1.&#xD;
TRANSPLANT: Patients receive peripheral blood stem cell infusion on day 0.&#xD;
GVHD PROPHYLAXIS: Patients then receive cyclophosphamide IV over 3 hours on days 3-4, tacrolimus IV beginning day 5 then PO for 6 months, mycophenolate mofetil PO BID or TID beginning day 5 for 6 weeks, and G-CSF SC beginning day 7 until neutrophil recovery is &gt; 1,500/mm^3.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (JAK inhibitor, conditioning, GVHD prophylaxis)</arm_group_label>
    <other_name>(-)-Cyclophosphamide</other_name>
    <other_name>2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate</other_name>
    <other_name>Carloxan</other_name>
    <other_name>Ciclofosfamida</other_name>
    <other_name>Ciclofosfamide</other_name>
    <other_name>Cicloxal</other_name>
    <other_name>Clafen</other_name>
    <other_name>Claphene</other_name>
    <other_name>CP monohydrate</other_name>
    <other_name>CTX</other_name>
    <other_name>CYCLO-cell</other_name>
    <other_name>Cycloblastin</other_name>
    <other_name>Cycloblastine</other_name>
    <other_name>Cyclophospham</other_name>
    <other_name>Cyclophosphamid monohydrate</other_name>
    <other_name>Cyclophosphamide Monohydrate</other_name>
    <other_name>Cyclophosphamidum</other_name>
    <other_name>Cyclophosphan</other_name>
    <other_name>Cyclophosphane</other_name>
    <other_name>Cyclophosphanum</other_name>
    <other_name>Cyclostin</other_name>
    <other_name>Cyclostine</other_name>
    <other_name>Cytophosphan</other_name>
    <other_name>Cytophosphane</other_name>
    <other_name>Cytoxan</other_name>
    <other_name>Fosfaseron</other_name>
    <other_name>Genoxal</other_name>
    <other_name>Genuxal</other_name>
    <other_name>Ledoxina</other_name>
    <other_name>Mitoxan</other_name>
    <other_name>Neosar</other_name>
    <other_name>Revimmune</other_name>
    <other_name>Syklofosfamid</other_name>
    <other_name>WR- 138719</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>JAK Inhibitor</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Treatment (JAK inhibitor, conditioning, GVHD prophylaxis)</arm_group_label>
    <other_name>Ruxolitinib</other_name>
    <other_name>Fedratinib</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (JAK inhibitor, conditioning, GVHD prophylaxis)</arm_group_label>
    <other_name>Fluradosa</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Recombinant Granulocyte Colony-Stimulating Factor</intervention_name>
    <description>Given SC</description>
    <arm_group_label>Treatment (JAK inhibitor, conditioning, GVHD prophylaxis)</arm_group_label>
    <other_name>Recombinant Colony-Stimulating Factor 3</other_name>
    <other_name>rhG-CSF</other_name>
    <other_name>143011-72-7</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Melphalan</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (JAK inhibitor, conditioning, GVHD prophylaxis)</arm_group_label>
    <other_name>Alanine Nitrogen Mustard</other_name>
    <other_name>CB-3025</other_name>
    <other_name>L-PAM</other_name>
    <other_name>L-Phenylalanine mustard</other_name>
    <other_name>L-sarcolysin</other_name>
    <other_name>L-Sarcolysin Phenylalanine mustard</other_name>
    <other_name>L-Sarcolysine</other_name>
    <other_name>Melphalanum</other_name>
    <other_name>Phenylalanine Mustard</other_name>
    <other_name>Phenylalanine Nitrogen Mustard</other_name>
    <other_name>Sarcoclorin</other_name>
    <other_name>Sarkolysin</other_name>
    <other_name>WR-19813</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mycophenolate Mofetil</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Treatment (JAK inhibitor, conditioning, GVHD prophylaxis)</arm_group_label>
    <other_name>Cellcept</other_name>
    <other_name>MMF</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Peripheral Blood Stem Cell Transplantation</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (JAK inhibitor, conditioning, GVHD prophylaxis)</arm_group_label>
    <other_name>PBPC transplantation</other_name>
    <other_name>PBSCT</other_name>
    <other_name>Peripheral Blood Progenitor Cell Transplantation</other_name>
    <other_name>peripheral stem cell support</other_name>
    <other_name>Peripheral Stem Cell Transplant</other_name>
    <other_name>peripheral stem cell transplantation</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tacrolimus</intervention_name>
    <description>Given IV and PO</description>
    <arm_group_label>Treatment (JAK inhibitor, conditioning, GVHD prophylaxis)</arm_group_label>
    <other_name>FK 506</other_name>
    <other_name>Fujimycin</other_name>
    <other_name>Hecoria</other_name>
    <other_name>Prograf</other_name>
    <other_name>Protopic</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Total-Body Irradiation</intervention_name>
    <description>Undergo TBI</description>
    <arm_group_label>Treatment (JAK inhibitor, conditioning, GVHD prophylaxis)</arm_group_label>
    <other_name>TBI</other_name>
    <other_name>Total Body Irradiation</other_name>
    <other_name>Whole Body Irradiation</other_name>
    <other_name>Whole-Body Irradiation</other_name>
    <other_name>Total-Body Irradiation Prior to Stem Cell Transplant</other_name>
    <other_name>SCT_TBI</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  PART 1: JAK INHIBITOR ADMINISTRATION INCLUSION CRITERIA&#xD;
&#xD;
          -  Diagnosis of primary myelofibrosis (PMF) as defined by the 2016 World Health&#xD;
             Organization classification system or diagnosis of secondary MF as defined by the&#xD;
             International Working Group (IWG) for Myeloproliferative Neoplasms Research and&#xD;
             Treatment criteria&#xD;
&#xD;
          -  Patients meeting the criteria for intermediate-1, intermediate-2 or high-risk disease&#xD;
             by the Dynamic International Prognostic Scoring System (DIPSS)-plus scoring system&#xD;
             (DIPSS may be used if all data from DIPSS are not available)&#xD;
&#xD;
          -  Ability to understand and the willingness to sign a written informed consent document&#xD;
             (or legally authorized representative)&#xD;
&#xD;
          -  Patient must be a potential hematopoietic stem cell transplant candidate&#xD;
&#xD;
          -  PART 2: ALLOGENEIC STEM CELL TRANSPLANT INCLUSION CRITERIA&#xD;
&#xD;
          -  Meeting criteria for 1st phase as above, at time of initiation of JAK inhibitor,&#xD;
             including ability to understand and willingness to sign a written informed consent.&#xD;
             Patients arriving to our institution for transplant and not enrolled in Part 1 may&#xD;
             still be enrolled in Part 2 if Part 1 criteria met. These patients will have Part 1&#xD;
             endpoints transcribed from medical records&#xD;
&#xD;
          -  Received JAK inhibitor for at least 8 weeks immediately prior to conditioning and be&#xD;
             able to continue until day -4 pre-transplant&#xD;
&#xD;
          -  Karnofsky performance status score &gt;= 70&#xD;
&#xD;
          -  Calculated creatinine clearance using the Cockcroft-Gault formula or 24 hour (hr)&#xD;
             urine creatinine clearance must be &gt; 60 ml/min&#xD;
&#xD;
          -  Total serum bilirubin must be &lt; 3 mg/dL unless the elevation is thought to be due to&#xD;
             Gilbert's disease or hemolysis&#xD;
&#xD;
          -  Transaminases must be &lt; 3 x the upper limit of normal&#xD;
&#xD;
          -  Patients with clinical or laboratory evidence of liver disease will be evaluated for&#xD;
             the cause of liver disease, its clinical severity in terms of liver function, and the&#xD;
             degree of portal hypertension. Patients with fulminant liver failure, cirrhosis with&#xD;
             evidence of portal hypertension or bridging fibrosis, alcoholic hepatitis, hepatic&#xD;
             encephalopathy, or correctable hepatic synthetic dysfunction evidenced by prolongation&#xD;
             of the prothrombin time, ascites related to portal hypertension, bacterial or fungal&#xD;
             abscess, biliary obstruction, chronic viral hepatitis with total serum bilirubin &gt; 3&#xD;
             mg/dL, and symptomatic biliary disease will be excluded&#xD;
&#xD;
          -  Diffusion capacity of the lung for carbon monoxide (DLCO) corrected &gt; 60% normal; may&#xD;
             not be on supplemental oxygen&#xD;
&#xD;
          -  Left ventricular ejection fraction &gt; 40% OR shortening fraction &gt; 26%&#xD;
&#xD;
          -  Comorbidity Index &lt; 5 at the time of pre-transplant evaluation&#xD;
&#xD;
          -  DONOR: Patients must be screened prior to transplant for donor-specific anti-HLA&#xD;
             antibodies (DSA). Patients with DSA will be reviewed by the principal investigator and&#xD;
             considered for desensitization treatment&#xD;
&#xD;
          -  DONOR: Children are preferred over siblings and parents&#xD;
&#xD;
          -  DONOR: Younger donors are preferred over older donors&#xD;
&#xD;
          -  DONOR: ABO matched donors are preferred over minor ABO mismatched and over major ABO&#xD;
             mismatch donors&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  PART 1: JAK INHIBITOR ADMINISTRATION EXCLUSION CRITERIA&#xD;
&#xD;
          -  Contraindication to receiving a JAK inhibitor including:&#xD;
&#xD;
               -  Patients who have known hypersensitivity to JAK inhibitors&#xD;
&#xD;
               -  Clinical or laboratory evidence of significant renal or hepatic impairment&#xD;
                  including cirrhosis&#xD;
&#xD;
               -  Active uncontrolled infection&#xD;
&#xD;
               -  Known human immunodeficiency virus (HIV) positivity&#xD;
&#xD;
               -  Women who are pregnant or trying to conceive&#xD;
&#xD;
               -  Caution should be used in patients with platelets &lt; 100 though adjustments in&#xD;
                  dose can be made to accommodate anyone with platelets &gt; 50&#xD;
&#xD;
          -  History of prior allogeneic transplant&#xD;
&#xD;
          -  Leukemic transformation (&gt; 20% blasts)&#xD;
&#xD;
          -  PART 2: ALLOGENEIC STEM CELL TRANSPLANT EXCLUSION CRITERIA&#xD;
&#xD;
          -  Uncontrolled viral or bacterial infection at the time of study enrollment&#xD;
&#xD;
          -  Active or recent (prior 6 month) invasive fungal infection without infectious disease&#xD;
             (ID) consult and approval&#xD;
&#xD;
          -  Known HIV positivity&#xD;
&#xD;
          -  Pregnant or breastfeeding&#xD;
&#xD;
          -  Availability of an human leukocyte antigen (HLA)-identical or 1-allele-mismatched&#xD;
             related donor or an HLA 10 of 10 matched unrelated donor&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rachel B. Salit</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fred Hutch/University of Washington Cancer Consortium</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Rachel B. Salit</last_name>
    <phone>206-667-1317</phone>
    <email>rsalit@fredhutch.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Fred Hutch/University of Washington Cancer Consortium</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rachel B. Salit</last_name>
      <phone>206-667-1317</phone>
      <email>rsalit@fredhutch.org</email>
    </contact>
    <investigator>
      <last_name>Rachel B. Salit</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>April 28, 2020</study_first_submitted>
  <study_first_submitted_qc>April 28, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 30, 2020</study_first_posted>
  <last_update_submitted>May 25, 2021</last_update_submitted>
  <last_update_submitted_qc>May 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Primary Myelofibrosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mycophenolic Acid</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Melphalan</mesh_term>
    <mesh_term>Mechlorethamine</mesh_term>
    <mesh_term>Nitrogen Mustard Compounds</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Tacrolimus</mesh_term>
    <mesh_term>Sargramostim</mesh_term>
    <mesh_term>Lenograstim</mesh_term>
    <mesh_term>Janus Kinase Inhibitors</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

